DEF: AEON Biopharma Seeks Shareholder Approval for Critical Financing and Equity Plan

AEON Biopharma, Inc. is calling a Special Meeting of Stockholders on January 21, 2026, to approve a private placement, an exchange of convertible notes, and an amended equity incentive plan, all crucial for funding the development of ABP-450 as a biosimilar to BOTOX.

Summary

• A Special Meeting of Stockholders will be held on January 21, 2026, at 8:00 a.m. Pacific Time in Irvine, California.
• Stockholders will vote on four proposals: the PIPE Financing Proposal, the Exchange Proposal, the Equity Plan Proposal, and the Adjournment Proposal.
• The PIPE Financing Proposal involves the issuance and sale of 4,616,924 shares of Class A common stock (or pre-funded warrants), warrants to purchase 6,581,829 shares, and True-Up Warrants, expected to raise approximately $11.4 million upon warrant exercise.
• The Exchange Proposal entails exchanging outstanding senior secured convertible notes held by Daewoong Pharmaceutical Co, Ltd. for approximately 23.1 million shares of Common Stock (or pre-funded warrants), a new $1.5 million senior secured convertible note, and a warrant to purchase 8,000,000 shares, with the Daewoong Warrant exercise expected to raise approximately $8.8 million.
• The Equity Plan Proposal seeks to approve the Amended and Restated 2023 Incentive Award Plan, increasing the number of shares authorized for issuance thereunder by 17,288,059 shares.
• Both the PIPE Financing Proposal and the Exchange Proposal are conditioned on each other's approval by stockholders.
• The Board of Directors unanimously recommends voting FOR all proposals, stating these transactions are crucial to fund the development and potential commercialization of ABP-450 as a biosimilar to BOTOX.
• The company has experienced recurring losses from operations, a net capital deficiency, and negative cash flows since its inception, reporting cash and cash equivalents of $5.9 million and an accumulated deficit of $433.7 million as of September 30, 2025.
• The company expects to have sufficient cash to fund its operating plan into the second quarter of 2026, including funds anticipated from the first and second closings of the PIPE Financing.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, a substantial accumulated deficit, and a 'going concern' warning. The failure of Phase 2 migraine trials and subsequent discontinuation of those programs are major setbacks. While the strategic pivot to a biosimilar pathway for ABP-450 and recent capital raises provide some liquidity and a new direction, the company remains in a precarious financial position, requiring further capital and successful execution of its new strategy.

Positives

• The company has strategically reprioritized its focus to a Section 351(k) biosimilar regulatory pathway for ABP-450, using BOTOX as a reference product, and has aligned with the FDA on next steps.
• Initial analytical studies indicate a 100% amino acid sequence match between ABP-450 and BOTOX, with highly similar potency across two distinct assays (LD50 and CBPA) and comparable vial-to-vial active ingredient composition.
• The proposed biosimilar pathway could improve provider reimbursement for ABP-450 by calculating Average Selling Price (ASP) based solely on therapeutic sales, potentially offering a competitive net price compared to products with combined cosmetic and therapeutic indications.
• A Phase 2 study of ABP-450 for cervical dystonia met all primary and key secondary endpoints, supporting further development in this indication.
• The PIPE financing and convertible note exchange are expected to provide critical funding, totaling approximately $11.4 million from PIPE and $8.8 million from Daewoong warrant exercise, for ABP-450 development.
• The company secured $18.3 million in net proceeds from a public offering in January 2025, contributing to its liquidity.
• Cash and cash equivalents increased from $13 thousand at December 31, 2024, to $5.9 million at September 30, 2025.

Negatives

• The company has experienced recurring losses from operations, a net capital deficiency, and negative cash flows since its inception.
• An accumulated deficit of $433.7 million was reported as of September 30, 2025.
• Phase 2 clinical trials for episodic and chronic migraine did not meet their primary or secondary endpoints, leading to the discontinuation of these development programs.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• The company received a notice of non-compliance from NYSE American due to stockholders' equity falling below the $2.0 million minimum requirement.
• Significant shareholder dilution is expected from the PIPE financing and the Daewoong convertible note exchange, with existing shareholders' ownership estimated at 26.1% post-transactions.
• Outstanding Private Placement Warrants have an exercise price of $828.00, significantly higher than the common stock price of $0.935 (as of November 10, 2025), making cash exercise unlikely.
• A loss on issuance of warrants of $75.6 million was recognized in the first quarter of fiscal 2025.
• The company settled a lawsuit with Odeon Capital Group LLC for $1.0 million cash, $0.3 million in shares, and 125,000 warrants, indicating past legal liabilities.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital, which may not be available on commercially reasonable terms or at all.
• Future equity financings would dilute existing shareholders.
• There is no assurance of obtaining regulatory approval for ABP-450 as a biosimilar to BOTOX.
• Uncertainty exists regarding the broad adoption of any approved products by physicians and patients.
• The company faces significant competition in the pharmaceutical industry.
• Dependency on Daewoong Pharmaceutical Co., Ltd. as an exclusive and sole supplier for ABP-450 poses a risk, as the license agreement could terminate under certain conditions.
• The NYSE American may initiate delisting proceedings if the company fails to regain compliance with listing standards by August 3, 2026.
• The New Convertible Note to Daewoong includes covenants restricting the company's ability to issue senior or pari passu debt without Daewoong's prior written consent, and junior debt except as expressly permitted.
• Upon an event of default, Daewoong will be entitled to foreclose on substantially all of the company's assets, which are subject to a first-priority security interest.

Future Outlook

The company expects to incur losses and use cash in its operations for the foreseeable future. It aims to fund the development and potential commercialization of ABP-450 as a biosimilar to BOTOX. The company plans to perform additional analytical studies and prepare for a Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the second half of 2025. A Phase 3 study in cervical dystonia may commence pending analytical results and FDA discussions. The company anticipates having sufficient cash to fund its operating plan into the second quarter of 2026, including anticipated PIPE financing funds, and will actively attempt to secure additional capital. Research and development expenses are expected to be significant, while selling, general and administrative expenses are projected to decrease in the near term due to the biosimilar strategy pivot, offset by increased costs associated with being a public company.

Management Comments

• "The transactions are crucial steps to fund the development and potential commercialization of ABP-450 as a biosimilar to BOTOX. Therefore, your vote on the proposals at the Special Meeting is very important." Robert Bancroft, President, Chief Executive Officer and Director.
• "We believe that completing the Second Closing and the Exchange will allow us to fund the development and potential commercialization of ABP-450 as a biosimilar to Botox." Board of Directors.

Industry Context

The company operates in the biopharmaceutical industry, specifically targeting the global therapeutic botulinum toxin market, estimated at $3.0 billion and projected to grow to $4.4 billion by 2027. Its strategic pivot to develop ABP-450 as a biosimilar to AbbVie Inc.'s BOTOX positions it within the growing biosimilar segment. This strategy aims to differentiate ABP-450 by pursuing a therapeutic-only Biologics License Application (BLA) under Section 351(k), which could allow for an Average Selling Price (ASP) calculation based solely on therapeutic sales. This approach is intended to improve provider reimbursement and offer a competitive net price, addressing a challenge faced by existing botulinum toxins that combine cosmetic and therapeutic sales in their ASP calculations.

Comparison to Industry Standards

• ABP-450 demonstrated a 100% amino acid sequence match with BOTOX, based on liquid chromatography/mass spectrometry (LC/MS) analysis of over 3,400 peptides across multiple lots, with 93% to 99% sequence coverage for the five proteins comprising the 900kD botulinum toxin type A complex.
• ABP-450 showed highly similar potency across two distinct assays (LD50 in vivo biological activity and CBPA cell-based potency assay) to BOTOX, supporting clinical dose predictability.
• Comparable vial-to-vial active ingredient composition using ELISA further supports dose similarity and reliability with BOTOX.
• Functional cleavage of SNAP-25 by ABP-450 is consistent with the mechanism of action of BOTOX.
• The company's strategy to pursue a therapeutic-only BLA under Section 351(k) for ABP-450 is unique within the current therapeutic neurotoxin market, aiming to avoid the dilution of Average Selling Price (ASP) that affects physician reimbursement for therapeutic uses of competitors like BOTOX, which are approved for both cosmetic and therapeutic indications.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed by Odeon Capital Group LLC on September 18, 2023, alleging the company failed to pay a $1.25 million deferred underwriting fee.
• The company successfully obtained dismissal of Odeon's non-breach of contract claims in April 2024.
• The breach of contract claim is proceeding, with summary judgment motions filed by both parties in March 2025.
• A settlement agreement was reached on October 31, 2025, with Odeon for $1.0 million in cash, $0.3 million in shares of common stock, and 125,000 warrants.

Related Party Transactions

• Daewoong Pharmaceutical Co, Ltd. (Daewoong) is a key related party, holding outstanding senior secured convertible notes from the company.
• An exchange agreement with Daewoong is proposed for these notes, involving shares, a new $1.5 million convertible note, and a warrant to purchase 8,000,000 shares.
• Daewoong is the exclusive and sole supplier for ABP-450 under a license and supply agreement.
• Seongsoo Park, a member of the Board, is affiliated with Daewoong and was nominated by Daewoong as part of the Exchange Agreement.
• Alphaeon 1 LLC (A1) was involved in previous convertible note agreements and committed financing.

Stakeholder Impact

• Shareholders face significant dilution from the proposed PIPE financing and Daewoong exchange, with existing shareholders' ownership estimated to decrease to 26.1% post-transactions.
• Shareholders are being asked to vote on critical proposals that will shape the company's financial future and capital structure.
• There is a risk of delisting from NYSE American if the company fails to regain compliance with listing standards, which would negatively impact shareholders.
• The Equity Plan proposal aims to attract, motivate, and retain key employees and directors through equity-based incentives, potentially benefiting long-term company performance.
• Creditors, particularly Daewoong, will exchange existing convertible notes for a new senior secured convertible note, shares, and warrants, and will hold a first-priority security interest on substantially all of the company's assets with foreclosure rights upon default.
• The continued development of ABP-450 as a biosimilar to BOTOX for debilitating medical conditions could potentially offer a more accessible or competitively priced treatment option for patients and healthcare providers.

Next Steps

• Stockholders to vote on the PIPE Financing, Exchange, and Equity Plan Proposals at the Special Meeting on January 21, 2026.
• Consummation of the Second Closing of the PIPE Financing and the Exchange is contingent on stockholder approval of both proposals.
• The company will perform additional analytical studies for its ABP-450 biosimilar program.
• An anticipated Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA is scheduled for November 19, 2025, to review analytical study results.
• The company may commence a Phase 3 study in cervical dystonia pending analytical results and FDA discussions.
• The company will actively attempt to secure additional capital to fund operations beyond the second quarter of 2026.
• The company must regain compliance with NYSE American listing standards by August 3, 2026.
• A Current Report on Form 8-K will be filed with the SEC within four business days after the Special Meeting to disclose voting results.

Key Dates

Recommendation

The company is in a highly precarious financial position, evidenced by recurring losses, a substantial accumulated deficit, a 'going concern' warning, and non-compliance with NYSE American listing standards. While the proposed financing and strategic pivot to a biosimilar pathway offer a potential lifeline, they also involve significant shareholder dilution and do not guarantee future profitability or regulatory success. The failure of previous Phase 2 trials for migraine indicates high development risk. Investors face substantial uncertainty and a high risk of further capital erosion. The current stock price is significantly below previous warrant exercise prices, indicating a loss of value.

Keywords

Biopharmaceutical, ABP-450, Botulinum Toxin, Biosimilar, BOTOX, SEC Filing, Proxy Statement, PIPE Financing, Convertible Notes, Equity Plan, NYSE American, Clinical Trials, Regulatory Approval, Going Concern, Shareholder Meeting, Daewoong Pharmaceutical, Dilution, Warrants, Cervical Dystonia, Migraine